Ascendis Pharma A (ASND) Profit After Tax (2014 - 2026)

Ascendis Pharma A has reported Profit After Tax for 13 years, with the latest figure at $736.8 million in Q1 2026.

• Quarterly Profit After Tax rose 640.23% year-over-year to $736.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $670.4 million (up 498.34% YoY) and the FY2025 annual result came in at -$265.4 million, up 34.3% from the prior year.
• Profit After Tax advanced to $736.8 million in Q1 2026 per ASND's latest filing, from -$39.1 million in the prior quarter.
• Over five years, Profit After Tax peaked at $736.8 million in Q1 2026 and troughed at -$211.6 million in Q4 2022.
• A 5-year average of -$14.6 million and a median of -$86.8 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2026: Profit After Tax slumped 2888983.71% in 2022, then jumped 640.23% in 2026.
• Over 5 years, Profit After Tax stood at -$211.6 million in 2022, then jumped by 55.83% to -$93.5 million in 2023, then surged by 56.02% to -$41.1 million in 2024, then climbed by 4.96% to -$39.1 million in 2025, then surged by 1985.95% to $736.8 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $736.8 million, -$39.1 million, and -$71.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.